HomeStock SectorsEnergy StocksShort-Term Stability vs. Long-Term...

Short-Term Stability vs. Long-Term Tension: Gas Market Holds Steady

This analysis was conducted in cooperation with Anastasia Volkova- analyst (LSE).

market signals remain mixed. Summer 2025 contracts held just above their median pre-expiry levels last week, staying within historical volatility ranges. In contrast, winter 2026-27 contracts remained firmly above the upper bounds of the 10-day pre-expiry band, reflecting persistent supply and weather-related risk. The forward curve, though flatter in the 3-year segment, remains notably distorted in both short and long tenors versus 2020-2024 benchmarks – a sign of lingering structural uncertainty.

Meanwhile, fundamentals are stabilizing: storage injections rebounded to +63 BCF, inventories rose above the 5-year median, and NOAA forecasts point to weather normalization by late July. Still, the supply-demand balance remains below historical norms, suggesting short-term calm is masking longer-term imbalances.

Current Prices Compared to Price Dispersion 10 Days Before Expiration by Month Since 2010

The price situation has remained virtually unchanged compared to last week. Summer 2025 contracts are trading a little bit above the median price at expiration, but remain within the interquartile range. Winter 2026 and 2027 contracts remain above the upper range. We expect prices to stabilize.

Forward Curve Compared to 2020-2024

Forward curve compared to 2020-2024

Despite the fact that 2025 contracts with delivery in three years’ time are close to the prices of 2023 and 2024 contracts with corresponding delivery terms, there remains a strong skew in the forward curve for near-term deliveries (1-2 years) and long-term deliveries (5-6 years).

Current Stocks and Forecast For Next Week Compared to 2019-2024

Current Stocks And Forecast For Next Week

For week 27 (June 28 – July 3), we expect an increase in storage of 63 BCF. The fill rate is above the median for the previous five years. Injection rates have recovered after last week’s decline, and if the current supply and demand conditions remain unchanged, peak levels for 2024 are possible. Weather and seasonal phenomena in the second half of summer remain a limiting factor.

Weekly HDD+CDD Total Based on Current NOAA Data and Forecast for the Next Two Weeks Compared to 1994-2024Weekly HDD+CDD

The weather is gradually stabilizing. Week 28 is expected to still be hot compared to the last 30 years, but on July 29, forecasts are reaching the median.

Explanation of the graph: the candles represent quantiles for 30 years from 1994 to 2024. Red dots are for 2024, green dots are for 2025, and blue dots are predictions for 2025.

Weekly HDD+CDD Total Based On Current NOAA Data and Forecast for the Next Two Weeks Compared to 1994-2024 by RegionWeekly HDD+CDD

If we look at the situation by region, we see a similar stabilization of weather conditions in virtually all regions.

Weekly Total Difference Between Supply and Demand Compared to 2014-2024Supply vs Demand

The contributing factors of the supply-demand difference still do not allow it to approach the median. In the current Week 28, the balance remains well below historical levels.

Afterword

While near-term fundamentals are regaining balance, the broader pricing structure continues to reflect deeper unease. The divergence along the forward curve suggests the market is still pricing in systemic risks, whether from policy shifts, infrastructure uncertainty, or long-term demand volatility.

Regional weather normalization and storage growth offer short-term relief, but they haven’t yet translated into a restored supply-demand equilibrium. For now, sentiment appears cautiously neutral: anchored by recent injections, yet shadowed by unresolved structural signals farther out on the curve.

Most Popular

More from Author

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But...

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday...

Read Now

FDA Grants Complete Approval To Moderna’s COVID-19 Vaccine For Children As Young As 6 Months – Moderna (NASDAQ:MRNA)

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s MRNA supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.The company’s COVID-19 vaccine, mRNA-1273, was previously available...

US Dollar Holds Steady as Trump Threatens 50% Tariffs on Brazil

Trump announces fresh round of tariffs on Brazil and smaller nations But only mild risk aversion as Nvidia (NASDAQ:) drives equities higher, hits $4 trillion cap Fed minutes erase July cut bets as doves in the minority, dollar supported Bitcoin hits record high, comes just shy of $112,000 Trump Stuck in...

The Market Everyone Gave Up On Is Crushing Nasdaq 100 In 2025 – Global X MSCI Greece ETF (ARCA:GREK), Invesco QQQ Trust, Series 1...

Greece's 2010 collapse was so severe it leased islands, gutted public jobs and pensions, while some abroad even joked about selling the Acropolis to appease creditors.Fast forward 15 years, and the picture couldn't be more different.The Athens Stock Exchange has soared nearly 34% year-to-date, making Greece the...

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study – Pfizer (NYSE:PFE)

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence...

The Powell-Trump Clash is Set to Escalate

Growth challenges are mounting while tariffs will lift inflation, but stagflation fears are wide of the mark. The Fed will likely delay rate cuts until the end of the year, despite escalating pressure from the president, but may move in larger steps when it does cutConsumer Caution...

Why Is AbbVie Stock Trading Higher On Thursday? – AstraZeneca (NASDAQ:AZN), AbbVie (NYSE:ABBV)

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.“Multispecifics including trispecific antibodies represent...

Dynamic Hedging and FX Risk Analysis Within Tactical Asset Allocation Rules

Often, investors fully hedge their portfolios for currency risk. This can lead to significant drag in performance for currencies with negative carry. However, not hedging the foreign currency exposure can lead to significant drawdowns, especially for conservative investments. In this paper, we consider a conservative, global tactical...

German CPI Confirmed at 2.0%, Euro Drifting, FOMC Split Over Cuts

The euro continues to have a quiet week and is drifting for a third consecutive day. In the European session, is trading at 1.1730, up 0.09% on the day.German Inflation Dips to 2% as food, Energy Prices FallGerman inflation rose 2.0% y/y in June, in line...

Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble? – Klotho Neurosciences (NASDAQ:KLTO)

Shares of Klotho Neurosciences, Inc. KLTO have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS treatment candidate. What's Driving The Rally: Klotho announced it has received...

Eurozone Economic Weakness Laid Bare as US Front-Loading Effects Wane

Eurozone data remains volatile amid trade war developments, but the underlying trend is still sluggish. Uncertainty is slowing domestic demand, which contributes to our expectation of a further rate cut from the European Central Bank in SeptemberEurozone Economy Shows Further Weakness in the Second QuarterThe eurozone economy...

SeaStar Medical’s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka – Johnson & Johnson...

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern. That's particularly true regarding pediatric AKI – each year, about 4,000 children with AKI require continuous renal replacement therapy (RRT), with a mortality rate of approximately 51-58%. Many of those...

Why Are Biotech Stocks Ultragenyx And Mereo Facing A Sell-Off? – Ultragenyx Pharmaceutical (NASDAQ:RARE), Mereo BioPharma Group (NASDAQ:MREO)

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.What Happened?The companies on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward...